mementor develops and distributes digital medical products in sleep medicine and related fields. Originally founded in 2014 in Switzerland by Dr. Noah Lorenz, Alexander Rötger, Jan Kühni, and Daniel Rotzetter, mementor has had its headquarters in Leipzig since January 2020. mementor's "Apps on prescription" aim to address the limitations of conventional patient care. The goal is to remove treatment barriers and enable affected individuals to access evidence-based therapy methods.

Our team aims to provide affected individuals with effective digital health products to effectively treat physical or mental illnesses. At the same time, we want to help close existing gaps in healthcare and actively shape the future of digital medicine. High scientific standards, an evidence-based approach, stringent data protection requirements, and patient safety are our priorities.

Both information security and patient safety are priorities at mementor. mementor is certified according to the DIN EN ISO/IEC 27001 standard and meets all related information security requirements. With the quality management system certification according to DIN EN ISO 13485, mementor demonstrates that all necessary measures are taken to manufacture high-quality medical products. Compliance with these standards is verified annually through internal and external audits to ensure the highest quality and safety.

somnio is an "App on prescription" for sleep disorders developed in collaboration with sleep medicine specialists and psychologists. It is the first permanently approved digital health application (DiGA) since October 2020 for treating insomnia. The app uses cognitive behavioral therapy for insomnia (CBT-I) translated into various modules to improve individual sleep behavior sustainably within three months. Its effectiveness has been scientifically proven through randomized studies.

actensio is the first "App on prescription" approved for hypertension treatment, offering a low-threshold, guideline-compliant therapy option. It supports patients effectively on a behavioral medicine basis to implement recommended lifestyle changes for long-term blood pressure control and reduces their personal risks of heart attack and stroke. Its effectiveness is also demonstrated by randomized clinical studies.

The content of mementor's health applications is based on thoroughly researched treatment techniques. The effectiveness of these products is supported by clinical studies of the highest scientific standards (randomized controlled trials).

Since August 2, 2022, mementor DE GmbH is part of ResMed in Germany. Together, they aim to leverage their respective expertise to provide more people with effective, low-threshold access to alternative therapy options for sleep disorders and close care gaps. ResMed, a leading provider of therapy for sleep-related breathing disorders and respiratory diseases in outpatient care, expanded its portfolio in digital sleep medicine through this acquisition. mementor operates as an independent business unit within ResMed Germany and serves as the basis for future developments in digital health. Dr. Noah Lorenz and Katherina Jekerle, Senior Director Marketing and member of the management board at ResMed Germany, lead the management team.